Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 20/20 | 0.58 |
| ▸ | EGFR | P00533 | 2/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | ABL2 | P42684 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31463180 | 1.00 | SRC (0.58) | SRCEGFRABL1ABL2 | |
| SCHEMBL25417491 | 0.87 | SRC (0.59) | SRCEGFRABL1ABL2 | |
| SCHEMBL30035472 | 0.87 | SRC (0.59) | SRCEGFRABL1ABL2 | |
| SCHEMBL27194876 | 0.87 | SRC (0.59) | SRCEGFRABL1ABL2 | |
| SCHEMBL26791254 | 0.87 | SRC (0.64) | SRCEGFRABL1ABL2 | |
| SCHEMBL30404376 | 0.86 | SRC (0.63) | SRCEGFR | |
| SCHEMBL26789846 | 0.86 | SRC (0.63) | SRCEGFR | |
| SCHEMBL29588909 | 0.85 | SRC (0.60) | SRCEGFRABL1ABL2 | |
| SCHEMBL15345563 | 0.85 | SRC (0.60) | SRCEGFRABL1ABL2 | |
| SCHEMBL23854950 | 0.83 | SRC (0.49) | SRCEGFRABL1ABL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12492208-B2 | Crystal of pyrimidine compound | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2025-12-09 | — | — | US | disclosed |
| US-20240238300-A1 | TREATMENT METHODS FOR SUBJECTS WITH CANCER HAVING AN ABERRATION IN EGFR AND/OR HER2 | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| CN-113271950-B | Pyrimidine compound or salt thereof | 大鹏药品工业株式会社 | 2024-04-30 | — | — | CN | disclosed |
| EP-4351737-A2 | TREATMENT METHODS FOR SUBJECTS WITH CANCER HAVING AN ABERRATION IN EGFR AND/OR HER2 | Taiho Pharmaceutical Co., Ltd. (JP) | 2024-04-17 | — | — | EP | disclosed |
| EP-3909584-B1 | PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2023-12-13 | — | — | EP | disclosed |
| US-20230331730-A1 | CRYSTAL OF PYRIMIDINE COMPOUND | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-10-19 | — | — | US | disclosed |
| US-20230285397-A1 | EGFR INHIBITOR | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-09-14 | — | — | US | disclosed |
| US-20230255972-A1 | PYRIMIDINE COMPOUND-CONTAINING COMBINATION TO BE USED IN TUMOR TREATMENT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-08-17 | — | — | US | disclosed |
| EP-4197538-A1 | EGFR INHIBITOR | Taiho Pharmaceutical Co., Ltd. (JP) | 2023-06-21 | — | — | EP | disclosed |
| EP-4183788-A1 | CRYSTAL OF PYRIMIDINE COMPOUND | Taiho Pharmaceutical Co., Ltd. (JP) | 2023-05-24 | — | — | EP | disclosed |
| EP-4183395-A1 | PYRIMIDINE COMPOUND-CONTAINING COMBINATION TO BE USED IN TUMOR TREATMENT | Taiho Pharmaceutical Co., Ltd. (JP) | 2023-05-24 | — | — | EP | disclosed |
| WO-2022251095-A2 | TREATMENT METHODS FOR SUBJECTS WITH CANCER HAVING AN ABERRATION IN EGFR AND/OR HER2 | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2022-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331730-A1 | CRYSTAL OF PYRIMIDINE COMPOUND | DPYD, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, UMPS | SRC 1655/4885EGFR 3520/4885ABL1 2409/4885 |
| US-12492208-B2 | Crystal of pyrimidine compound | DPYD, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NT5C3B | SRC 1702/4885EGFR 3388/4885ABL1 2364/4885 |
| US-20230285397-A1 | EGFR INHIBITOR | EGFR, ERBB2, ERBB4 | SRC 17/4885EGFR 1/4885ABL1 10/4885 |
| US-20240238300-A1 | TREATMENT METHODS FOR SUBJECTS WITH CANCER HAVING AN ABERRATION IN EGFR AND/OR HER2 | EGFR, ERBB2, ERBB3 | SRC 21/4885EGFR 1/4885ABL1 6/4885 |
| US-20230255972-A1 | PYRIMIDINE COMPOUND-CONTAINING COMBINATION TO BE USED IN TUMOR TREATMENT | TYMP, DPYD, TYMS | SRC 1373/4885EGFR 385/4885ABL1 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.